chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Flu; Initial information regarding an unsolicited valid non-serious case received from a consumer (patient) via social media on 15-Dec-2020.  This case involves a patient of unknown demographics who always got the flu (influenza), while the patient received Influenza Vaccine.  The patient's medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medication was unknown.  On an unknown date, the patients received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number not reported) via unknown route in unknown administration site as prophylactic vaccination.  On an unknown date, the patient stated that he/she always got the flu (influenza) 7to 10 days after the patient got the shot.  It was not reported if the patient received a corrective treatment.  Outcome of the event was unknown, at the time of reporting.  There will be no information available on the batch number for this case.
I had open heart surgery the end of October to replace two artificial heart valves and to repair a third.  Was suffering from hemolytic anemia prior to that, along with worsening shortness of breath  After the surgery the anemia is no longer and am working with my cardiologist to monitor the healing and  slowly reducing medication.  After the vaccine I started having lightheadedness and through a heart monitor discovered a 5 second halt to my heart beat did occur.  Doctor advised me reduce my Blood Pressure medication and report the reaction to you since this started to happen after the vaccine.  I am on  a heart monitor and my Dr. is reducing my blood Pressure medication.  I postponed my Second Moderna shot to see if the condition improves.
redness at injection site; This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a 69-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concomitant products included Herpes zoster (Shingrix).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix and an unknown time after receiving Shingrix, the patient experienced injection site erythema. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the injection site erythema was recovered/resolved.   It was unknown if the reporter considered the injection site erythema to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported the event was lasted for few days and then resolved. The reporter consented to follow up. This case has been linked with case US2019229380 and US2019AMR231840, reported by same reporter.
Fever of 103.6; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever of 103.6) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 032M20A and 029M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 11-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 11-Mar-2021, the patient experienced PYREXIA (Fever of 103.6). The patient was treated with PARACETAMOL (TYLENOL) at a dose of 500 mg. On 12-Mar-2021, PYREXIA (Fever of 103.6) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 11-Mar-2021, Pyrexia: 103.6 (High) 103.6.         No concomitant medications were provided.
Urticaria-like rash on face, arms, legs 1-2 days after 3rd dose Prevnar
Patient received pfizer vaccine on 2/9/21, 3/9/21 and 10/8/21. Unsure of lot numbers. Presented to ER on 6/11/22 and found to be COVID positive. Sent from the nursing  home because of decreased p.o. intake, nausea, vomiting, and hypoxemia.  The  patient's ABG in the ER showed a pO2 of only 67.3.  He also tested positive  for COVID-19, but he really did not have an accurate onset of symptoms, but  possibly within the last 2 to 3 days, so he might still be benefitting from  remdisivir.lethargic, although he is saturating 94% on 6 L, but now he is off the non-rebreather. Admitted to hospital. Was on NC 6L. Received cefepime, doxycycline, and remdesivir. Discharged on 4/L NC on 6/16/22
The symptoms started on the evening of about 12/24/2021. From about 12/24-12/30, I had occasional coughing and sneezing, and I assumed I just had allergies. Then on 12/30/2021, the coughing and sneezing became constant. The following day, on 12/31/2021, I underwent a rapid test for COVID at Medical Center. On 1/1/2022, I got the results back, and they were positive. I had a breakthrough case! After my 10-day isolation, I had to go to the ER at Medical Center on one occasion, because the coughing and sneezing were still relentless. It was so bad, I felt like I couldn't catch my breath! I was told that this was a normal symptom of COVID and that it could last for several months. At the time of this writing, I still have the coughing, but it's usually at night and occasionally in the early morning.
Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 52-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 05Sep2022 as dose 4 (booster), single (Batch/Lot number: unknown) at the age of 51 years for covid-19 immunisation; BNT162b2 (BNT162B2), on 18Mar2022 as dose 3 (booster), single (Batch/Lot number: unknown), in right arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Obesity" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "Treatment of COVID-19". Therapeutic measures were taken as a result of drug ineffective, covid-19. The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5, BNT162b2 has been requested and will be submitted if and when received.  Clinical course: The patient was treated with Paxlovid from 21Mar2023 to 26Mar2023 for covid-19.
Redness at injection site and tenderness. Patient not suffering from itching or burning. Patient has noticed increasing redness at injection site.
horrible chills; fever; felt like someone on her chest; big painful lesion in groin / spread on left side up buttocks; painful lesion in groin; Lymph nodes in groin are swollen / Injection / arm has swollen lymph nodes / she can't put arm down it's so puffy; nonstop headache; pain in back; cannot walk or lay down; legs have cramps when walking; This case was reported by a consumer via call center representative and described the occurrence of skin lesion in a 56-year-old female patient who received Herpes zoster (Shingrix) (batch number 33TL7, expiry date 30th September 2022) for prophylaxis.   The patient's past medical history included lymph node excision and breast cancer.   On 15th October 2020, the patient received the 1st dose of Shingrix (intramuscular). In October 2020, less than a week after receiving Shingrix and an unknown time after starting acyclovir, the patient experienced skin lesion, wound pain, enlargement of lymph nodes, headache, back pain, mobility decreased and leg cramps. On 15th October 2020, the patient experienced chills, fever and chest abnormal feeling of. The patient was treated with acyclovir, paracetamol (Tylenol) and antibiotics nos (Antibiotic Ointment (Unknown Ingredients)). On 17th October 2020, the outcome of the chills, fever and chest abnormal feeling of were recovered/resolved. On an unknown date, the outcome of the skin lesion was resolved with sequelae and the outcome of the wound pain was not recovered/not resolved and the outcome of the enlargement of lymph nodes, headache, back pain, mobility decreased and leg cramps were unknown.   It was unknown if the reporter considered the skin lesion, wound pain, enlargement of lymph nodes, headache, back pain, mobility decreased, leg cramps, chills, fever and chest abnormal feeling of to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The has no lymph nodes on the left arm due to breast cancer surgery. The patient had 1st dose of Shingrix in right arm via intramuscular route. The patient said that she never had shingles and was perfectly healthy before Shingrix administration. The patient had a big painful lesion in groin. The lesion required treatment with Acyclovir and antibiotic ointment. The lymph nodes in groin were swollen and lesion had spread on left side up buttocks. The patient took nonstop Tylenol for nonstop headache. The patient reported that the complete located from kidneys to all the way down the pain in back and could not walk or lay down. The patient had legs cramps when walking. The injection right arm had swollen lymph nodes and could not put arm down as it was so puffy. The patient had horrible chills at beginning, fever, felt like someone on her chest and had resolved till the time of report. The reporter consented to follow up.
Agitation reported in pt who recvd flu vax; agitation 12 hrs p/flu vax pt agitated x 1.5 hrs; sx cleared spontaneously; pt is also receiving HCTZ, & Theophylline, but not near time of agitation; pt has recvd flu vax w/o problems;
Patient given IM injection 11/14 into left arm. On 11/15, Nurse noticed arm was swollen and warm. Patient said the arm bothered her when it was tocuhed or if she moved. MD aware.
burning; burning on whole body; This case was reported by a consumer via call center representative and described the occurrence of injection site burning in a 64-year-old female patient who received Flu Seasonal QIV Dresden (Fluarix Quadrivalent 2019-2020 season) for prophylaxis.   Previously administered products included Flu vaccine (Several years ago the patient had a reaction to a flu vaccine that caused a skin crawling sensation. This lasted for almost one year before resolving. At that time she thought it might be due to the thimerosal in the vaccine).   On 22nd August 2019, the patient received Fluarix Quadrivalent 2019-2020 season (intramuscular). On 22nd August 2019, less than a day after receiving Fluarix Quadrivalent 2019-2020 season, the patient experienced injection site burning and burning sensation. On an unknown date, the outcome of the injection site burning and burning sensation were not recovered/not resolved.   It was unknown if the reporter considered the injection site burning and burning sensation to be related to Fluarix Quadrivalent 2019-2020 season.  Additional case details were reported as follows: The patient received vaccine in unknown arm. On evening of 22nd August 2019, the patient started having a burning sensation in her arm around the injection site. The burning later spread to the whole side of her body, and then to her whole body. The reporter did not consent to follow up.
103.5 Fever, Nausea, stomach pain, sore muscles, vomiting. Motrin to relieve pain and reduce fever, cool cloths on forehead. Lasted for 48 hours.
About 9 hours later I experienced fever and muscular pain.  Symptoms were partially alleviated by ibuprofen. By the next morning I experienced significant pressure in my bladder consistent with urinary tract infection. I was alarmed enough by this to make a drs appointment. Fortunately this subsided in about an hour and a half and I cxld the appt. The remainder of this day I felt tired and achy. At about 4 pm I took another dose of ibuprofen as I started to feel feverish again.  By the morning of Nov 1 I was feeling back to normal.
Soreness/Achiness; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Soreness/Achiness) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history information was reported.  Concomitant products included CITALOPRAM, HYDROCHLOROTHIAZIDE and SIMVASTATIN for an unknown indication.   On 24-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Feb-2021, the patient experienced PAIN (Soreness/Achiness). On 25-Feb-2021, PAIN (Soreness/Achiness) had resolved.            No treatment information was provided.   This case was linked to MOD-2021-418822, MOD-2021-419760 (Patient Link).
Discharge Provider: DO Primary Care Provider: PA Admission Date: 9/29/2022 Discharge Date: Oct 2, 2022  PRESENTING PROBLEM: Acute respiratory failure with hypoxia (HCC) [J96.01]   HOSPITAL COURSE: The patient is a  64 y.o. male with past medical history of HTN, HLD, obesity, OSA and venous insufficiency who presented to the ED with hypoxia. He was subsequently found to be COVID positive and initiated on treatment with remdesivir and decadron. He was also covered for CAP with ceftriaxone and azithromycin.   He subsequently weaned to room air with no oxygen needs on pulm rehab consultation and was able to be discharged to home on 10/2/22.  He was transitioned of oral Ceftin and Zmax to finish a 5 days course and continued on Decadron oral to finish 10 days.     Wound care was consulted for his wound management, but was unable to see him prior to d/c.  It was recommended he have close follow up with his PCP.
Dizziness and passed out, became extremely confused and couldn't remember anything. Went to ER.
45 min after to receiving IM flu vaccine noticed itching at injection site, arm and trunk. Blurred vision and cognitive impairment. Went to hospital ER.
Fever, loss of equilibrium, weakness, feelings of needing to urinate but can't. Inability to stand, walk, or move around. Pour apatite. Fell while trying to make it back to my daughters car. Got home and laid down with ice pack. Fell again on my way to bed. Remained in bed for most of the time but fell again when I tried to get up. Was given Tylenol  for the fever, ice packs and icyhot for the bruises.
My father had an acute myocardial infarction.  He was perfectly fine the Sunday before and earlier the day of.  On Monday April 26th he had sudden onset of c/o a headache didnt feel well that then led to c/o jaw neck pain.  He sat down eyes rolled back 911 EMS dispatched
unsure of onset of sx either 14AUG98 evening or 15AUG98AM sx were red, raised itchy spots/small than twenty five cent on back chest & both arms;fever 102 for first day & one half;
Initial report received from healthcare professional on 30 April 2012. An 18-year-old female patient, whose medical history included history of allergy to tree nuts and not to eggs and concomitant medications were not reported, had received subcutaneous dose of YF-VAX (batch number UH277AA), at left arm on 23 April 2012. On 30 April 2012 i.e. 7 days after the vaccination, the patient experienced pressure in her "axillary" area and under her breast. She also had redness around the area of vaccination. The lab details and corrective treatment details were not reported. The outcome of event was not reported. Documents held by sender: None.
This report has been received from the nurse reported that VARIVAX (Merck) (lot # H020587, expiration date 13-NOV-2014) and PROQUAD (Merck) (MARRS# 1311USA012185) were trough unsupported temperature excursions on 26-JUN-2013, 01-JUL-2013, 22-JUL-2013 thru 31-JUL_2013 and the entire month of August 2013. On 23-AUG-2013 the patient was administered the unsupported VARIVAX (Merck) (dose and route not reported). This is one of several reports received from the same source (MARRS# 1311USA002616, 1312USA003307, 1312USA003308, 1312USA003306, 1312USA003310, 1312USA003311, 1312USA003312, 1312USA003313, 1312USA003314, 1312USA003315, 1312USA003316, 1312USA003317). Additional information is not expected.
This case was reported by a healthcare professional and described the occurrence of swollen axillary nodes in a 5-year-old male subject who was vaccinated with INFANRIX, MMR II (Merck). Concurrent vaccination included IPOL and unspecified vaccine PPD both given on 7 May 2008. On 7 May 2008 at 09:45 the subject received 5th booster dose of INFANRIX at 0.5 ml, intramuscularly in the left arm and 2nd dose of MMR II vaccine at 0.5 ml subcutaneously in the right tricep. Approximately 12 to 24 hours later, on 8 May 2008, the subject experienced swollen axillary nodes, erythema, swelling and itching. Also reported was pain in axillary node and a warm axillary node. Erythema, swelling and itching resolved at an unspecified time. Swelling of the axillary node was unresolved. The outcome of the axillary node tenderness and warm axillary node was not specified. While being seen for these events in the physician's office, it was noted that the subject received a 4th dose of INFANRIX intramuscularly in the left deltoid on 30 March 2007. According to the reporter, this dose of INFANRIX was not needed. This was considered to be an extra dose administered. The healthcare professional considered the events of swollen axillary node, erythema, swelling and itching to be probably related to vaccination with INFANRIX and MMR II vaccine. Follow-up information received on 16 June 2008 indicated that the events were unresolved and possibly related to treatment with INFANRIX. The subject's mother reportedly called the reporter on 23 May 2008 and stated that her daughter's axillary node was still enlarged. She also mentioned that it was not tender. Swollen axillary gland was documented in follow-up.
Syncopal episode in the lobby of the office and fell to the floor striking his right parietal scalp with associated loss of consciousness for less than 1 minute, then was confused with severe headache and a right parietal cephalhematoma. Was admitted to hospital for observations.
Soreness, hot and red arm, headache, dizziness immediately after vaccine. When home hot red arm symptom went away only to bring chills, fever, fatigue, severe joint and muscle pain throughout my entire body, irritability, headache, and weakness. It has now been a few days all of the muscle and joint pain continues to get worse, headache, fatigue, irritability, and weakness is still present.
Developed pain and redness as site with marked induration of subcutaneous tissues (aprox 2 x 2 cm) with redness and warmth of overlying skin.  Marked margins and observed for 3-4 hours and erythema progressing.  Started on oral bactrim and flagyl
Unknown Brand or lot numbers of Vaccines  Patient had Covid booster shot (3rd injection) on October 5th along with getting Flu vaccine as well as Shingrex at an different facility,  Admitted to Hospital on 10/13/21 with Diagnosis: Principal Problem:   Acute metabolic encephalopathy Active Problems:   Seizure (CMS/HCC)   Altered mental status   Fever Neurologic:  Metabolic encephalopathy, secondary meningitis vs paraneoplastic vs autoimmune vs. Seizure vs post-vaccination
Gave shot to low in arm, hit the nerve and the versa which is causing pain at the location of the injection and it goes all the way  down to the hand...the pain is constant and its been 4 months
Concerned that she was developing Guillain-Barré syndrome; Urinary incontinence with burning; Hematuria; Fever; chills; Urinary incontinence with burning; This case was reported by a nurse via call center representative and described the occurrence of guillain barre syndrome in a female patient who received Flu Seasonal QIV Dresden (Fluarix Quadrivalent 2019-2020 season) (batch number K72SN, expiry date 30th June 2020) for prophylaxis.   On 8th October 2019, the patient received Fluarix Quadrivalent 2019-2020 season. On 8th October 2019, less than a day after receiving Fluarix Quadrivalent 2019-2020 season, the patient experienced guillain barre syndrome (serious criteria GSK medically significant), urinary incontinence, hematuria, fever, chills and micturition burning. The patient was treated with ciprofloxacin. On an unknown date, the outcome of the guillain barre syndrome was unknown and the outcome of the urinary incontinence, hematuria, fever, chills and micturition burning were recovering/resolving.   It was unknown if the reporter considered the guillain barre syndrome, urinary incontinence, hematuria, fever, chills and micturition burning to be related to Fluarix Quadrivalent 2019-2020 season.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Fluarix Quadrivalent 2019-2020 season and developed urinary incontinence with burning, hematuria, fever and chills within 4 to 5 hours. The patient had not seen her PCP but self-treated at home with Ciprofloxacin. The patient was concerned that she was developing Guillain-Barre syndrome. The patient had not sought treatment from a provider. The symptoms had not fully resolved at the time of the call. The reporter consented to follow up.
Became weak; Couldn't walk well; This spontaneous case was reported by a physician and describes the occurrence of GAIT INABILITY (Couldn't walk well) and ASTHENIA (Became weak) in a 26-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Dec-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Dec-2021, the patient experienced GAIT INABILITY (Couldn't walk well). On 29-Dec-2021, the patient experienced ASTHENIA (Became weak). At the time of the report, GAIT INABILITY (Couldn't walk well) and ASTHENIA (Became weak) had not resolved.      mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported. It was reported that, on the same day, she was not the same person. She couldn't walk well and became weak the next day.  No treatment medication was reported.   This case was linked to MOD-2022-497995 (Patient Link).   Reporter did not allow further contact
Loose stool; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Loose stool) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Dec-2020, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced DIARRHOEA (Loose stool). The patient was treated with LOPERAMIDE at an unspecified dose and frequency. At the time of the report, DIARRHOEA (Loose stool) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient reported that he received both vaccines, and he had for five weeks loose stool.
p/vax pt devel h/a, stiff neck & a change in mental status, & was unable to walk;pt hosp;pt devel sz;8/1/99 pt died;initial eval & COD is aseptic meningitis;3 other cases viral meningitis is community during same time frame
Pt states that she is having muscle weakness/pain and difficulty breathing since the day after the administration, starting 11/27.
Patient was underage when given the Coiv 19 Moderna dose 1. Patients father requested for patient to received dose 2.
pt has swelling, redness and pain. 5 cm developing at site of injection right upper arm.